Cabozantinib - Exelixis/Ipsen

Drug Profile

Cabozantinib - Exelixis/Ipsen

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Duke University Medical Center; Exelixis; Ipsen; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum; Takeda
  • Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Preregistration Liver cancer
  • Phase II Adrenocortical carcinoma; Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Acute myeloid leukaemia; Astrocytoma; Cancer; Colorectal cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 19 Sep 2018 Registered for Renal cell carcinoma (Late-stage disease, Second-line therapy or greater) in Canada (PO)
  • 19 Sep 2018 Cabozantinib receives priority review status for Renal cell carcinoma in Canada before September 2018
  • 24 Aug 2018 Peloton Therapeutics plans a phase II trial for Renal cell carcinoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT03634540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top